Alzheimer's Disease Clinical Trial
Official title:
Effects and Mechanisms of Aerobic Exercises Combined With Dual-task Training in Cognitive Function in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease
Recent studies have shown that aerobic exercises and dual-task training are effective in
improving overall cognitive function in patients with cognitive impairment or dementia.
However, the biological mechanisms are unknown in humans. It also remains unclear regarding
whether carrying APOEε4 genotype or not would influence the effects. Therefore, the three
main purposes of this study are: (1) to investigate the effects of a 3-month aerobic
exercises combined with dual-task training on memory and executive cognitive functions in
patients with mild cognitive impairment (MCI) and in those with early Alzheimer's disease
(AD); (2) to compare the differences in training effects between patients who carry APOEε4
genotype and those who do not carry this genotype; and (3) to investigate the biological
mechanisms of the exercise training effects on memory and executive cognitive function in
these patients. The biological mechanisms of interest will include the blood Aβ1-40 and
Aβ1-42 level, insulin, fasting glucose, cytokine, integrity of brain fiber tracts, and
cerebral blood flow.
We will conduct a randomized controlled clinical trial. A total of 70 patients with MCI or
AD will be recruited. The participants will be randomly assigned to the experimental group
or the control group. Both groups will receive three 90-minute exercise sessions per week
for 12 weeks. For the experimental group, the exercise program will include moderate
intensity aerobic exercises and dual-task training; whereas for the control group, the
training program will include gentle stretching exercises. Both groups will receive
examinations on outcome variables, including blood Aβ1-40 and Aβ1-42 level, insulin, fasting
glucose, cytokine,integrity of brain fiber tracts, cerebral blood flow, cognitive function,
and dual task performance at baseline, post-training, and after a 3-month follow-up period.
Differences on the aforementioned outcomes brought by the 12-week training programs will be
compared between the experimental and control groups. Exercise effects between patients who
carry APOEε4 genotype and those who do not will also be examined.
Results of this study will provide relevant clinical evidence for the effects of aerobic
exercises combined with dual-task training on patients with MCI and mild AD; and will
provide further understanding of the mechanisms mediating these effects.
Recent studies have shown that moderate-to-high intensity aerobic exercises are effective in
improving overall cognitive function in patients with cognitive impairment or dementia.
Dual-task training programs also show positive effects on enhancing executive function in
patients with cognitive impairment. However, the biological mechanisms through which these
training effects are mediated remain largely unknown in humans. It also remains unclear
regarding whether carrying APOEε4 genotype or not would influence the effects of aerobic
exercises and dual-task training on cognitive function of these patients. Therefore, the
three main purposes of this study are:
1. to investigate the effects of a 3-month aerobic exercises combined with dual-task
training on memory and executive cognitive functions in patients with mild cognitive
impairment (MCI) and in those with early Alzheimer's disease (AD);
2. to compare the differences in training effects between patients who carry APOEε4
genotype and those who do not carry this genotype; and
3. to investigate the biological mechanisms of the exercise training effects on memory and
executive cognitive function in these patients. The biological mechanisms of interest
will include the blood Aβ1-40 and Aβ1-42 level, insulin, fasting glucose, cytokine
(TNF-α, Interleukin(IL) -Iβ, IL-6, CRP),integrity of brain fiber tracts, and cerebral
blood flow.
We will conduct a single-blind (assessor blinded) randomized controlled clinical trial. A
total of 70 patients with MCI or AD will be recruited. The participants will be randomly
assigned to the experimental group or the control group using stratified randomization by
matching patient's diagnosis. Both groups will receive one health education session and
three 90-minute exercise sessions per week for 12 weeks. For the experimental group, the
exercise program will include moderate intensity aerobic exercises and dual-task training;
whereas for the control group, the training program will include gentle stretching exercises
and activities in sitting of mild intensity. Both groups will receive examinations on
outcome variables, including blood Aβ1-40 and Aβ1-42 level, insulin, fasting glucose,
cytokine (TNF-α, IL-Iβ, IL-6, CRP),integrity of brain fiber tracts, cerebral blood flow,
cognitive function, and dual task performance at baseline, post-training, and after a
3-month follow-up period. Differences on the aforementioned outcomes brought by the 12-week
training programs will be compared between the experimental and control groups using two-way
(group x time) repeated measures of ANOVA. Intercorrelations among the changes in these
outcomes will be analyzed to explore the possible biological mechanisms mediating the
training effects. Exercise effects between patients who carry APOEε4 genotype and those who
do not will also be examined.
Results of this study will provide relevant clinical evidence for the effects of aerobic
exercises combined with dual-task training on patients with MCI and mild AD; and will
provide further understanding of the mechanisms mediating these effects.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT01826110 -
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
|
Phase 1 |